You are here: Industry Insights > multiple myeloma

News List

Going Global Successfully! BCMA CAR-T of Legend Biotech is Approved by FDA for Marketing! PharmaSources/Small pill
March 16, 2022
On February 28 local time, LEGN.US officially announced in Somerset, New Jersey, U.S., that its self-developed BCMA-targeted CAR-T therapy, ciltacabtagene autoleucel (trade name: CARVYKTI®), abbreviated as Cilta-cel, was approved for marketing by the FDA.
Yangtze River Receiving Another 2 Clinical Trial Implied Permissions CPhI.CN
April 27, 2020
Yangtze River Receiving Another 2 Clinical Trial Implied Permissions in the Battle for the First Generic of the Blockbuster MM Drug Pomalidomide.
HaemaLogiX and Lonza Collaborate to Manufacture KappaMab, a Multiple Myeloma Drug Candidate prnasia
January 29, 2022
HaemaLogiX Ltd (HaemaLogiX), the clinical-stage biotechnology company developing novel monoclonal antibody therapies for multiple myeloma, and Lonza, a global development and manufacturing partner to the pharma...
I-Mab Announces Partnership Agreement to Localize Manufacturing and Accelerate Commercialization of Innovative Biologics Drugs prnasia
January 29, 2022
I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics...
Bristol-Myers Squibb’s Abecma gets approval in Japan for multiple myeloma ExpressPharma
January 24, 2022
The approval for Abecma is based on data obtained from the Phase II Study BB2121-MM-001 and the Phase I Study CRB-401.
GSK unveils Target the Future, a global, multi-year programme to help address key challenges affecting the multiple myeloma community WorldPharmaNews
December 02, 2021
GlaxoSmithKline (GSK) plc today launched Target the Future, an international, multi-year initiative dedicated to advancing innovation and addressing key needs in the multiple myeloma community. The programme will provide education on progress in ...
Gracell Biotechnologies Granted FDA Orphan Drug Designation for FasTCAR-enabled BCMA/CD19 Dual-targeting CAR-T Cell Therapy Candidate GC012F for the Treatment of Multiple Myeloma prnasia
November 22, 2021
Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer...
JW Therapeutics Announces IND Approval for the Clinical Trial of JWCAR129 prnasia
September 28, 2021
JW Therapeutics (HKEx: 2126), an innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, today announced that it has received the Investigational New Drug...
Multiple Myeloma Patients Display Weakened Antibody Responses to mRNA COVID Vaccines firstwordpharma
August 02, 2021
A new study reports weakened antibody responses to COVID-19 mRNA vaccines among most patients with multiple myeloma, a common form of bone-marrow cancer associated with an immunocompromised state.
Sanofi to license multiple myeloma target domain from Eureka and MSK pharmaceutical-technology
July 08, 2021
Sanofi has signed a licence agreement with Eureka Therapeutics and Memorial Sloan Kettering Cancer Center (MSK) for non-CAR use of a new human binding domain for the potential treatment of multiple myeloma.

Previous page 1 2 3 4 5 6 7 8 9 Next page